Tissue Repair Nears FDA Submission with 100 Patients Randomised and Strong Cash

Phase III Trial Progress and Regulatory Milestones

Tissue Repair (ASX:TRP) is inching closer to a pivotal moment in its US Phase III clinical trial for chronic wounds, having randomised approximately 100 patients so far, with recruitment continuing at about 10 new patients per month. This steady enrolment pace keeps the company on track to submit its FDA 510(k) medical device application in October 2026, a key regulatory milestone that could open the door to commercialisation in the lucrative US market.

Following the FDA submission, Tissue Repair also plans to file for a European CE Mark Class II, aiming to broaden its market reach across multiple jurisdictions.

Favourable US Reimbursement Landscape Emerges

April 2026 regulatory changes in the US have created a more attractive commercial environment for Tissue Repair’s lead product, TR-987. Preliminary reimbursement analysis suggests that treatment of a 10cm² chronic wound could attract reimbursement of around US$1,270 per 10g tube in wound clinic settings. The company expects to retain about 60% of this amount, indicating potentially healthy margins pending payer adoption.

While final reimbursement outcomes will depend on post-approval payer decisions, this development significantly enhances the commercial viability of TR-987, positioning it well within a competitive medical device framework.

Australian Commercial Launch and Manufacturing Efficiency Gains

On the commercial front, Tissue Repair has completed its first Good Manufacturing Practice (GMP) production run of TR Pro+ in Australia, with three product formats (10g, 30g, and 200g) set to launch imminently. Despite initial delays due to manufacturing partner validation, the company is now poised to expand product availability.

Sales through Advanced Cosmeceuticals remain modest, under 3,000 tubes per month, roughly matching prior internal sales levels before the distribution handover in September 2025.

Notably, the company has materially reduced manufacturing scale-up costs by securing a second-hand centrifuge, which is expected to speed up pilot API production without the burden of significant capital expenditure. This move reflects a pragmatic approach to managing operational expenses amid ongoing R&D investment.

Financial Position and Strategic Initiatives

Tissue Repair closed the June quarter with $4.76 million in cash, bolstered by a $1.9 million R&D tax refund received post-quarter and an estimated $2.2 million refund anticipated for FY26. Including these inflows, the cash position as of 1 July 2026 stands at a solid $6.66 million.

Operating cash outflows for the quarter totalled $1.848 million, driven mainly by R&D expenditure ($1.09 million), manufacturing costs ($308k), and staff and marketing expenses. These outflows underline the company’s commitment to advancing its clinical and commercial programs.

Strategic milestones ahead include ongoing clinical trial recruitment, the FDA and CE Mark submissions, manufacturing scale-up with new equipment arriving soon, and the establishment of a Medical Advisory Board chaired by Dr Steven Liew, expected to commence in September 2026.